$9.86
2.95% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US50127T1097
Symbol
KURA

Kura Oncology, Inc. Stock price

$9.86
+0.43 4.56% 1M
+4.22 74.67% 6M
+1.15 13.20% YTD
-7.91 44.51% 1Y
-3.77 27.66% 3Y
-27.91 73.89% 5Y
+1.16 13.33% 10Y
-5.14 34.27% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.30 2.95%
ISIN
US50127T1097
Symbol
KURA
Industry

Key metrics

Basic
Market capitalization
$858.0m
Enterprise Value
$236.9m
Net debt
positive
Cash
$630.7m
Shares outstanding
86.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.3 | 9.4
EV/Sales
2.8 | 2.6
EV/FCF
1.9
P/B
2.8
Financial Health
Equity Ratio
54.4%
Return on Equity
-42.1%
ROCE
-38.2%
ROIC
-39,684.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$83.3m | $90.9m
EBITDA
$-218.8m | $-269.9m
EBIT
$-219.7m | $-244.1m
Net Income
$-197.2m | $-221.1m
Free Cash Flow
$122.9m
Growth (TTM | estimate)
Revenue
- | 68.6%
EBITDA
-9.8% | -40.3%
EBIT
-9.8% | -26.3%
Net Income
-8.5% | -27.1%
Free Cash Flow
179.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-262.8% | -297.0%
EBIT
-263.8%
Net
-236.8% | -243.4%
Free Cash Flow
147.5%
More
EPS
$-2.3
FCF per Share
$1.4
Short interest
12.3%
Employees
192
Rev per Employee
$280.0k
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Kura Oncology, Inc. forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
83 83
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 90 90
45% 45%
108%
- Research and Development Expense 213 213
54% 54%
255%
-219 -219
10% 10%
-263%
- Depreciation and Amortization 0.88 0.88
1% 1%
1%
EBIT (Operating Income) EBIT -220 -220
10% 10%
-264%
Net Profit -197 -197
8% 8%
-237%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisti...
Neutral
Seeking Alpha
4 days ago
Kura Oncology, Inc. ( KURA ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Greg Mann Thomas Doyle - Senior Vice President of Finance & Accounting Troy Wilson - Chairman, CEO & President Mollie Leoni - Chief Medical Officer Brian Powl - Chief Commercial Officer Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Jason Zemansky - BofA...
Neutral
GlobeNewsWire
4 days ago
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today